Ritter Pharmaceuticals (RTTR) could be worth $7 in the next year
What’s up with Ritter Pharmaceuticals?
Ritter Pharmaceuticals (RTTR) opened at $0.67, which means the stock is down 15% from yesterday’s closing price of 0.72. Today, the company has a high of $0.71 and a low of $0.58. The company has a market cap of $28.33 million with a 52-week high of $1.27 and a 52-week low of $0.15.
What about the future for Ritter Pharmaceuticals?
The high forecast for Ritter Pharmaceuticals is $7.00 while the low is $0.60. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Ritter Pharmaceuticals has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information RTTR seems to be a safe buy.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.